Various biochemical compounds are under development to actually augment this immune response to be used in conjunction with the EGFRI therapy [68], most prominently Imprime PGG (Biothera) has shown to improve survival even in the KRAS mutant colorectal cancer patients when used in combination with cetuximab (Erbitux) [69, 70]. Here, KRAS is linked to colorectal cancer.